CareLit · DOI-Nachweis · Klinische Pädiatrie
A regulatory BCL2 promoter polymorphism (-938C>A) is associated with outcome in neuroblastoma
DOI 10.1055/s-0030-1254469
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Brockmeyer, H Bachmann, A Künkele, W Siffert, A Eggert, A Schramm, J Schulte, K Pajtler
ZeitschriftKlinische Pädiatrie
Ausgabe05/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Expression of the BCL-2 anti-apoptotic protein correlates with adverse outcome of neuroblastoma and confers chemoresistance to neuroblastoma cells. BCL2, therefore, serves as a bona fide drug target in neuroblastoma. With the development of BCL-2 inhibitors, a new therapeutic option is now available for evaluation. We hypothesized that a regulatory BCL2–938C>A promoter polymorphism, which significantly affects promo…
Zitieren
Zitierempfehlung
B Brockmeyer, H Bachmann, A Künkele, W Siffert, A Eggert, A Schramm, J Schulte, K Pajtler (2010) A regulatory BCL2 promoter polymorphism (-938C>A) is associated with outcome in neuroblastoma. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0030-1254469
Mit CareLit weiterarbeiten